Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system: Effect of opioids

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system : Effect of opioids. / Mark, Esben Bolvig; Klinge, Mette Winther; Grønlund, Debbie; Poulsen, Jakob Lykke; Schlageter, Vincent; Scott, S. Mark; Krogh, Klaus; Drewes, Asbjørn Mohr.

I: Neurogastroenterology and Motility, Bind 32, Nr. 3, e13753, 03.2020.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Mark, EB, Klinge, MW, Grønlund, D, Poulsen, JL, Schlageter, V, Scott, SM, Krogh, K & Drewes, AM 2020, 'Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system: Effect of opioids', Neurogastroenterology and Motility, bind 32, nr. 3, e13753. https://doi.org/10.1111/nmo.13753

APA

Mark, E. B., Klinge, M. W., Grønlund, D., Poulsen, J. L., Schlageter, V., Scott, S. M., Krogh, K., & Drewes, A. M. (2020). Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system: Effect of opioids. Neurogastroenterology and Motility, 32(3), [e13753]. https://doi.org/10.1111/nmo.13753

CBE

Mark EB, Klinge MW, Grønlund D, Poulsen JL, Schlageter V, Scott SM, Krogh K, Drewes AM. 2020. Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system: Effect of opioids. Neurogastroenterology and Motility. 32(3):Article e13753. https://doi.org/10.1111/nmo.13753

MLA

Vancouver

Mark EB, Klinge MW, Grønlund D, Poulsen JL, Schlageter V, Scott SM o.a. Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system: Effect of opioids. Neurogastroenterology and Motility. 2020 mar;32(3). e13753. https://doi.org/10.1111/nmo.13753

Author

Mark, Esben Bolvig ; Klinge, Mette Winther ; Grønlund, Debbie ; Poulsen, Jakob Lykke ; Schlageter, Vincent ; Scott, S. Mark ; Krogh, Klaus ; Drewes, Asbjørn Mohr. / Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system : Effect of opioids. I: Neurogastroenterology and Motility. 2020 ; Bind 32, Nr. 3.

Bibtex

@article{466c2c45b87d4d0babe4f7a0522f8d7d,
title = "Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system: Effect of opioids",
abstract = "Background: Opioid treatment often causes debilitating constipation. However, it is not well described how opioids affect colonic motility and whether opioid-induced constipation is due to either a decrease of powerful peristaltic contractions or “uncoordinated” peristalsis. The present study aims to investigate the effect of oxycodone on parameters of colonic motility and to determine whether motility is normalized by the opioid antagonist naloxegol. Methods: In two randomized, double-blind crossover trials, oxycodone or placebo was administered to 25 healthy males (Trial A), while another 24 healthy males were administered oxycodone with naloxegol or placebo (Trial B). Colonic motility was assessed by tracking the progression of an electromagnetic capsule throughout the large intestine. Segmental colonic transit times and capsule movements were calculated using displacement distance and velocity. Key Results: In Trial A, colonic transit time increased during oxycodone treatment compared with placebo (39 vs 18 hours, P <.01). Displacement during long fast antegrade movements was shorter during oxycodone treatment than with placebo (10 vs 20 cm, P =.03). In Trial B, colonic transit time was faster during oxycodone + naloxegol than during oxycodone + placebo (40 vs 55 hours, P =.049), mainly caused by an increase of the percentwise fraction of distance covered by fast movements in the left colon (P =.001). Conclusion & Inferences: Oxycodone treatment impaired colonic motility, manifested as increased transit time, specifically decreased long fast antegrade movements, and addition of naloxegol improved motility dynamics. In humans, the increased transit time during opioid treatment is caused by a decrease in long fast movements rather than uncoordinated peristalsis.",
keywords = "colon, electromagnetic capsule, motility, opioid antagonists, opioids, CONSTIPATION, MANAGEMENT, INDUCED BOWEL DYSFUNCTION, REGIONAL GASTROINTESTINAL TRANSIT, MORPHINE, PATHOPHYSIOLOGY, INSIGHTS",
author = "Mark, {Esben Bolvig} and Klinge, {Mette Winther} and Debbie Gr{\o}nlund and Poulsen, {Jakob Lykke} and Vincent Schlageter and Scott, {S. Mark} and Klaus Krogh and Drewes, {Asbj{\o}rn Mohr}",
year = "2020",
month = mar,
doi = "10.1111/nmo.13753",
language = "English",
volume = "32",
journal = "Neurogastroenterology and Motility Online",
issn = "1365-2982",
publisher = "Wiley-Blackwell Publishing Ltd.",
number = "3",

}

RIS

TY - JOUR

T1 - Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system

T2 - Effect of opioids

AU - Mark, Esben Bolvig

AU - Klinge, Mette Winther

AU - Grønlund, Debbie

AU - Poulsen, Jakob Lykke

AU - Schlageter, Vincent

AU - Scott, S. Mark

AU - Krogh, Klaus

AU - Drewes, Asbjørn Mohr

PY - 2020/3

Y1 - 2020/3

N2 - Background: Opioid treatment often causes debilitating constipation. However, it is not well described how opioids affect colonic motility and whether opioid-induced constipation is due to either a decrease of powerful peristaltic contractions or “uncoordinated” peristalsis. The present study aims to investigate the effect of oxycodone on parameters of colonic motility and to determine whether motility is normalized by the opioid antagonist naloxegol. Methods: In two randomized, double-blind crossover trials, oxycodone or placebo was administered to 25 healthy males (Trial A), while another 24 healthy males were administered oxycodone with naloxegol or placebo (Trial B). Colonic motility was assessed by tracking the progression of an electromagnetic capsule throughout the large intestine. Segmental colonic transit times and capsule movements were calculated using displacement distance and velocity. Key Results: In Trial A, colonic transit time increased during oxycodone treatment compared with placebo (39 vs 18 hours, P <.01). Displacement during long fast antegrade movements was shorter during oxycodone treatment than with placebo (10 vs 20 cm, P =.03). In Trial B, colonic transit time was faster during oxycodone + naloxegol than during oxycodone + placebo (40 vs 55 hours, P =.049), mainly caused by an increase of the percentwise fraction of distance covered by fast movements in the left colon (P =.001). Conclusion & Inferences: Oxycodone treatment impaired colonic motility, manifested as increased transit time, specifically decreased long fast antegrade movements, and addition of naloxegol improved motility dynamics. In humans, the increased transit time during opioid treatment is caused by a decrease in long fast movements rather than uncoordinated peristalsis.

AB - Background: Opioid treatment often causes debilitating constipation. However, it is not well described how opioids affect colonic motility and whether opioid-induced constipation is due to either a decrease of powerful peristaltic contractions or “uncoordinated” peristalsis. The present study aims to investigate the effect of oxycodone on parameters of colonic motility and to determine whether motility is normalized by the opioid antagonist naloxegol. Methods: In two randomized, double-blind crossover trials, oxycodone or placebo was administered to 25 healthy males (Trial A), while another 24 healthy males were administered oxycodone with naloxegol or placebo (Trial B). Colonic motility was assessed by tracking the progression of an electromagnetic capsule throughout the large intestine. Segmental colonic transit times and capsule movements were calculated using displacement distance and velocity. Key Results: In Trial A, colonic transit time increased during oxycodone treatment compared with placebo (39 vs 18 hours, P <.01). Displacement during long fast antegrade movements was shorter during oxycodone treatment than with placebo (10 vs 20 cm, P =.03). In Trial B, colonic transit time was faster during oxycodone + naloxegol than during oxycodone + placebo (40 vs 55 hours, P =.049), mainly caused by an increase of the percentwise fraction of distance covered by fast movements in the left colon (P =.001). Conclusion & Inferences: Oxycodone treatment impaired colonic motility, manifested as increased transit time, specifically decreased long fast antegrade movements, and addition of naloxegol improved motility dynamics. In humans, the increased transit time during opioid treatment is caused by a decrease in long fast movements rather than uncoordinated peristalsis.

KW - colon

KW - electromagnetic capsule

KW - motility

KW - opioid antagonists

KW - opioids

KW - CONSTIPATION

KW - MANAGEMENT

KW - INDUCED BOWEL DYSFUNCTION

KW - REGIONAL GASTROINTESTINAL TRANSIT

KW - MORPHINE

KW - PATHOPHYSIOLOGY

KW - INSIGHTS

UR - http://www.scopus.com/inward/record.url?scp=85075063768&partnerID=8YFLogxK

U2 - 10.1111/nmo.13753

DO - 10.1111/nmo.13753

M3 - Journal article

C2 - 31721398

AN - SCOPUS:85075063768

VL - 32

JO - Neurogastroenterology and Motility Online

JF - Neurogastroenterology and Motility Online

SN - 1365-2982

IS - 3

M1 - e13753

ER -